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even in the stable post-MI 1-year survivors who received current state-
of-art therapeutics. Further larger studies are needed to deﬁne the
high-risk group in Korean stable post-MI survivors.
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BACKGROUND Current guidelines recommend appropriate revascu-
larization and optimal medical treatment (OMT) including antiplatelet
therapy, statin, beta-blocker, or renin-angiotensin system (RAS)
blocker in the treatment of acute myocardial infarction (AMI). The
purpose of this study is to describe the prescription status for OMT
and long-term clinical outcome according to the status for OMT at
discharge and at 1-year.
METHODS We consecutively enrolled AMI patients who underwent
percutaneous coronary intervention (PCI) in the COREA-AMI (CardiOvas-
cular Risk and idEntiﬁcAtion of potential high-risk population in AMI)
registry including nine major university hospitals throughout South Korea
from January 2004 to December 2009. OMTwas deﬁned as taking all three
medications including statin, beta-blocker, and RAS blocker (angiotensin
converting enzyme inhibitor or angiotensin receptor blocker) with dual
antiplatelet agent (DAPT) at discharge or with one or more antiplatelet
agent at 1 year. The primary endpoint was all-cause death and landmark
analysis for 1-year post-MI survivors were performed.
RESULTS Of 4,748 AMI patients, 2,517 were taking OMT with DAPT and
1,878 were not taking OMT at discharge. At 1 year, 1,719 were prescribed
OMT with one or more antiplatelet 1,845 were not prescribed OMT among
4,200whowere aliveat 1 year stablywithoutnon-fatalMIor stroke.Median
follow-up duration was 43.8 months (interquartile range 29.8 to 60.5
months).Within theﬁrst year, the incidence ratesofprimaryendpointwere
2.3% in OMT group and 5.4% in non-OMT group [Unadjusted HR (95%CI)
2.32 (1.69-3.19), p<0.001]. After 1 year from index PCI, all-cause deathwere
5.6% inOMTgroup and9.8% innon-OMTgroup [1.92 (1.43-2.59), p<0.001].
In multivariable Cox proportional hazards regression, non-OMT was inde-
pendent predictor for the primary endpointswithin the ﬁrst year [AdjustedHR 1.85 (1.34-2.57), p<0.001] and after 1 year from index AMI year [1.54
(1.14-2.09), p¼0.005]
CONCLUSIONS About 40% of post MI survivors were not prescribed
full OMT at the time of discharge or at 1 year. Long-term clinical
outcome was signiﬁcantly superior in the OMT group as compared
with non-OMT group not only within the ﬁrst year but also from 1 year
to study completion among stable post-MI 1 year survivors.
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BACKGROUND Clinical trials have failed to show a clear beneﬁt of
mechanical unloading of the left ventricle (LV) to limit ischemia-
reperfusion injury (IRI) in acute myocardial infarction (AMI), which
may reﬂect a poor understanding of whether to unload the LV before
or after reperfusion. We explored the kinetics of LV unloading with an
axial ﬂow catheter (Impella) in relation to balloon reperfusion as a
strategy to reduce infarct size and improve survival in AMI.
METHODS Weﬁrst employed a swinemodel of AMI. After 90minutes of
LAD occlusion, adult, male swine (n¼4.group) were randomized to
either: 1) 120 minutes of reperfusion alone (IRI), 2) 15, 30, or 60 minutes
of LV unloading before 120minutes of coronary reperfusion (Impella to
Balloon Group; ITB-15; ITB-30; ITB-60) or 3) 30 minutes of coronary
reperfusion followed by LV unloading and an additional 120 minutes of
reperfusion (Balloon to Impella Group; BTI-30). Infarct size,myocardial
kinase activity, and mitochondrial integrity were quantiﬁed. To begin
exploring the clinical utility of LV unloading before reperfusion we
retrospectively studied all patients in the USPella registry presenting
with acute ST-segment elevationmyocardial infarction and cardiogenic
shock who received an Impella within 120 minutes before (n¼41;
STEMI-ITB) or within 120 minutes after (n¼76; STEMI-BTI) percuta-
neous coronary reperfusion between 2009 and 2014.
RESULTS Compared to IRI alone, infarct size was reduced in the ITB-30
and ITB-60 groups, but not in the ITB-15 or BTI groups (Figure). Levels of
phosphorylated Akt, Erk-1/2, GSK3b and mitochondria per cardiomyocyte
were increasedwithin the infarct zone in the ITB-30and ITB-60groups, not
theBTI group. In the registry analysis, in-hospital (51%vs 28%,p¼0.02) and
30-day survival (42% vs 20%, p¼0.03) were higher in the STEMI-ITB than
the STEMI-BTI group.ASTEMI-ITB timeof less than60minutes (n¼38)was
associated with higher in-hospital survival than a STEMI-BTI time of less
than 60 minutes (n¼40) (50% vs 25%, p¼0.02).
